Showing 2,841 - 2,860 results of 3,102 for search '".gov"', query time: 0.07s Refine Results
  1. 2841

    Associated adverse outcomes with tumor treating fields when combined to temozolomide versus temozolomide alone for the treatment of glioblastoma: a meta-analysis of randomized tria... by Yuanyuan Chen, Yan Chen, Hong Zhen, Danhua Lou

    Published 2025-02-01
    “…Methods MEDLINE (subset PubMed), EMBASE, Web of Science, Cochrane databases, Google scholar, and http://www.ClinicalTrials.gov were searched for publications comparing TTF in combination with temozolomide versus temozolomide alone for the treatment of glioblastoma. …”
    Get full text
    Article
  2. 2842

    Readiness of adults with type 1 diabetes and diabetes caregivers for diabetes distress monitoring using a voice-based digital health solution: insights from the PsyVoice mixed meth... by Carine de Beaufort, Guy Fagherazzi, Aurélie Fischer, Till Seuring, Franchesca Aguirre Vergara, Gloria A Aguayo, India Pinker, Maria A Tichomirowa, Siri-Maria Kamp

    Published 2025-01-01
    “…Further research involving younger people with T1D could further contribute to the successful development of these tools.Trial registration number ClinicalTrials.gov, NCT05517772.…”
    Get full text
    Article
  3. 2843
  4. 2844
  5. 2845

    Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis by Shunlian Fu, Pingjin Zou, Zengyi Fang, Xinxiang Zhou, Junyang Chen, Cuicui Gong, Li Quan, Bing Lin, Qiu Chen, Jinyi Lang, Meihua Chen

    Published 2025-01-01
    “…Data sources We conducted a comprehensive search across the Medline, EMBASE, PubMed, and Web of Science databases, along with the ClinicalTrials.gov registry. Study selection Phase II/III randomized controlled trials (RCTs) investigating the effects of PARPi in metabolic and endocrine processes were selected for inclusion in patients with solid tumors. …”
    Get full text
    Article
  6. 2846
  7. 2847
  8. 2848
  9. 2849
  10. 2850
  11. 2851
  12. 2852
  13. 2853
  14. 2854
  15. 2855
  16. 2856

    Clinical trial to compare safety and tolerability between intravenous infusion and bolus intravenous injection of ApTOLL in healthy volunteers by Macarena Hernández-Jiménez, Samuel Martín-Vílchez, Gina Mejía-Abril, Manuel Roman, Sergio Luquero-Bueno, David Piñeiro, Marc Ribó, Francisco Abad-Santos, Dolores Ochoa

    Published 2025-03-01
    “…These results show that safety and pharmacokinetic profiles were comparable between intravenous infusion and bolus injection of ApTOLL, supporting a change of the route of administration for future clinical practice (ClinicalTrials.gov: NCT05569720).…”
    Get full text
    Article
  17. 2857

    Hypofractionated partial breast irradiation after breast-conserving surgery for patients with early stage breast cancer in China Mainland: a single-arm prospective trial by Xiaomeng Zhang, Xiaofang Wang, Zhuohua Xu, Yajuan Chu, Xingxing Chen, Li Zhang, Jin Meng, Wei Shi, Zhaozhi Yang, Xin Mei, Xiaoli Yu, Zhen Zhang, Xiaomao Guo, Miao Mo, Guangyu Liu, Jiong Wu, Zhimin Shao, Jinli Ma

    Published 2025-01-01
    “…This trial is registered with ClinicalTrials.gov (registration No. NCT03411174). From Jan of 2015 to July of 2018, 208 out of 222 patients recruited were evaluable and included in final analysis. …”
    Get full text
    Article
  18. 2858
  19. 2859

    Comparing efficacy and safety of low-dose versus standard-dose antiplatelet therapy in stroke patients: a meta-analysis by Zhao Ren, Chunxing Li, Xin Zhang, Lichaoyue Sun, Hui Zhu, Dongxiao Wang, Yumin Wang, Shuo Liang, Guanchun Wang

    Published 2025-01-01
    “…This requires careful dosage adjustments to balance thrombosis and bleeding risks.ObjectiveThis study compared the efficacy and safety of low-dose versus standard-dose antiplatelet therapy in stroke patients.MethodsWe conducted a comprehensive search across multiple databases, including PubMed, Embase, the Cochrane Library, ClinicalTrials.gov, CNKI, and the Wanfang Medical Database, up to March 2024. …”
    Get full text
    Article
  20. 2860